in disease activity associated with combination csDMARDs Methotrexate monotherapy is conditionally recommended over methotrexate plus a tumor necrosis factor (TNF) inhibitor for DMARD-naive patients with moderate-to-high disease activity Despite low-certainty evidence supporting greater improvement in disease activity with methotrexate plus a TNF inhibitor, methotrexate monotherapy is preferred over the combination because many patients will reach their goal on methotrexate monotherapy and